In keeping with this possibility, a study on osteosarcoma patients showed recurrent amplifications of the 16p13 region where MGRN1 is located [62], and another investigation reported hypomethylation of CpG sites in MGRN1 in blood cells from breast cancer patients [63]. Here, MGRN1 is linked to osteosarcoma.